Owen JB, Butterfield DA
4 Other than being on GLP-1s, higher risk patients include: those in the dose-escalation phase and those with upper GI symptoms (eg, nausea, vomiting, dyspepsia, abdominal distension, and abdominal discomfort/pain). 4 And obviously, other high-risk group includes patients with comorbidities associated with delayed gastric emptying (eg, poorly controlled diabetes, Parkinsons disease, bowel dysmotility) as well as those on other drugs that slow gastric emptying (eg, opioids, tricyclic antidepressants, marijuana, alcohol)
True carnitine deficiency is likely a result of genetic abnormalities in carnitine production or absorption
Meaningful body composition changes become visible during this phase
Once received, its effects highlight why glutathione is considered the most potent antioxidant